DrugPatentWatch Database Preview
ZEMDRI Drug Profile
When do Zemdri patents expire, and when can generic versions of Zemdri launch?
Zemdri is a drug marketed by Cipla Usa and is included in one NDA. There are four patents protecting this drug.
This drug has twenty-eight patent family members in twenty-one countries.
The generic ingredient in ZEMDRI is plazomicin sulfate. One supplier is listed for this compound. Additional details are available on the plazomicin sulfate profile page.
Summary for ZEMDRI
| International Patents: | 28 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for ZEMDRI |
| DailyMed Link: | ZEMDRI at DailyMed |
Generic Entry Opportunity Date for ZEMDRI
Generic Entry Date for ZEMDRI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for ZEMDRI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZEMDRI
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2011219498 | Start Trial |
| Japan | 4986310 | Start Trial |
| Canada | 2706369 | Start Trial |
| European Patent Office | 2217610 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
